Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) fell 3.7% on Thursday . The stock traded as low as $12.87 and last traded at $12.80. 235,663 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 2,603,448 shares. The stock had previously closed at $13.28.
Analysts Set New Price Targets
Several research analysts recently commented on DYN shares. Chardan Capital cut their price target on Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, July 29th. Guggenheim reiterated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Oppenheimer cut their price target on Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 6th. Royal Bank Of Canada cut their price target on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 29th. Finally, Robert W. Baird cut their price target on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 18th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $34.07.
Read Our Latest Report on Dyne Therapeutics
Dyne Therapeutics Price Performance
The company has a 50 day simple moving average of $11.30 and a 200-day simple moving average of $11.10. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -3.37 and a beta of 1.10. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.
Insider Buying and Selling at Dyne Therapeutics
In other news, CEO John Cox sold 2,640 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $13.41, for a total transaction of $35,402.40. Following the sale, the chief executive officer directly owned 199,539 shares in the company, valued at approximately $2,675,817.99. This represents a 1.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.77% of the company's stock.
Institutional Trading of Dyne Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. raised its position in shares of Dyne Therapeutics by 52.2% during the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company's stock worth $101,613,000 after purchasing an additional 3,333,248 shares during the period. Atlas Venture Life Science Advisors LLC raised its position in shares of Dyne Therapeutics by 13.9% during the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company's stock worth $95,505,000 after purchasing an additional 1,111,111 shares during the period. Vanguard Group Inc. raised its position in shares of Dyne Therapeutics by 10.5% during the 1st quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company's stock worth $77,470,000 after purchasing an additional 702,418 shares during the period. TCG Crossover Management LLC raised its position in shares of Dyne Therapeutics by 42.1% during the 2nd quarter. TCG Crossover Management LLC now owns 3,766,660 shares of the company's stock worth $35,859,000 after purchasing an additional 1,116,510 shares during the period. Finally, Braidwell LP raised its position in shares of Dyne Therapeutics by 431.6% during the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company's stock worth $37,879,000 after purchasing an additional 2,940,162 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Articles
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
